Search results
Results from the WOW.Com Content Network
A subsequent increase in PSA levels by 2.0 ng/mL [disputed – discuss] above the nadir is the currently accepted definition of prostate cancer recurrence after radiation therapy. [citation needed] Recurrent prostate cancer detected by a rise in PSA levels after curative treatment is referred to as a "biochemical recurrence". The likelihood of ...
The reduction in testosterone levels that occurs during GnRH antagonist therapy subsequently reduces the size of the prostate cancer. This in turn results in a reduction in prostate-specific antigen (PSA) levels in the patient's blood and so measuring PSA levels is a way to monitor how patients with prostate cancer are responding to treatment ...
Men without prostate cancer typically have PSA levels of under 4 nanograms per milliliter (ng/mL), according to the American Cancer Society. PSA levels between 4 and 10 suggest you could have ...
Prostate cancer is the uncontrolled growth of cells in the prostate, a gland in the male reproductive system below the bladder.Abnormal growth of the prostate tissue is usually detected through screening tests, typically blood tests that check for prostate-specific antigen (PSA) levels.
Bicalutamide also shows a better safety profile than cyproterone acetate. When used as a high-dosage monotherapy, bicalutamide shows slightly inferior effectiveness in the treatment of prostate cancer compared to castration and GnRH analogues but a different and potentially superior tolerability and safety profile.
Lowering androgen levels or stopping them from getting into prostate cancer cells often makes prostate cancer shrink or grow more slowly for a time. However, this treatment needs to be combined with radiation therapy (RT) [ 8 ] because ADT itself does not eradicate the cancer ; it just decreases its aggressiveness.
A digital rectal examination and the measurement of a prostate-specific antigen (PSA) level are usually the first investigations done to check for prostate cancer. PSA values are difficult to interpret, because a high value might be present in a person without cancer, and a low value can be present in someone with cancer. [28]
As PSA screening for prostate cancer declines, more men are being diagnosed with advanced disease that is less likely to respond to treatments, new research from the American Cancer Society finds.